Camden Capital, LLC Ascendis Pharma A/S Transaction History
Camden Capital, LLC
- $916 Million
- Q1 2025
A detailed history of Camden Capital, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Camden Capital, LLC holds 1,907 shares of ASND stock, worth $303,670. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,907Holding current value
$303,670% of portfolio
0.03%Shares
2 transactions
Others Institutions Holding ASND
# of Institutions
270Shares Held
61.9MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.64 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$873 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$831 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$715 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$678 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.89B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...